GM2 ganglioside (GM2) (GM2)

GM2 ganglioside is a sialic acid-containing glycosphingolipid primarily located on the outer leaflet of the plasma membrane (Livingston, 1995 [1]). While its expression in normal adult tissues is largely restricted to the central nervous system, it is significantly overexpressed on the surface of various neuroectoderm-derived tumors, such as melanoma, neuroblastoma, and sarcomas (Ragupathi, 1996 [2]). This differential expression pattern identifies GM2 as a prominent tumor-associated carbohydrate antigen (TACA) for targeted cancer immunotherapy (Zhang et al., 1997 [3]). In the context of malignancy, GM2 is involved in modulating cell signaling pathways and enhancing cell-to-cell adhesion, which facilitates tumor progression (Hakomori, 2001 [4]). Therapeutic approaches targeting GM2 include the use of conjugate vaccines like GM2-KLH to induce endogenous antibody production and monoclonal antibodies like BIW-8962 to mediate antibody-dependent cellular cytotoxicity (Chapman et al., 2000 [5]). Beyond oncology, GM2 is the primary storage material in Tay-Sachs disease, where genetic mutations in the HEXA gene lead to its pathological accumulation in neurons (Mahuran, 1999 [6]).

Other names

Monosialotetraosylganglioside GM2GalNAc-GM3II3Neu5Ac-Gg3CerGanglioside GM2Tumor-associated carbohydrate antigen GM2

Induction of humoral immune response and mediation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Chapman et al., 2000 [5]).